We are excited to announce that preclinical data on COR-1389, the first-in-class and best-in-class CRF2 receptor agonist, will be presented at EASD 2026 in Milan!
COR-1389 is designed to deliver weight loss while increasing lean muscle mass, offering a fundamentally different and efficient approach to obesity treatment. COR-1389 is finishing its Phase 1 in subjects living with obesity
Full abstract is available here :https://corteriapharma.com/wp-content/uploads/2026/09/EASD-2026.pdf